Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Aug;89(8):960-3.
doi: 10.1136/bjo.2004.053397.

Systemic hypertension and glaucoma: mechanisms in common and co-occurrence

M J S Langman  1 , R J Lancashire, K K Cheng, P M Stewart
Affiliations

Systemic hypertension and glaucoma: mechanisms in common and co-occurrence

M J S Langman et al. Br J Ophthalmol. 2005 Aug.

Abstract

Aims: To determine whether systemic hypertension and glaucoma might coexist more often than expected, with possible implications for treatment.

Methods: Case-control study using general practitioner database of patients with glaucoma matched with controls for age and sex.

Results: Hypertension was significantly more common in the 27,080 patients with glaucoma (odds ratio 1.29, 95% confidence intervals 1.23 to 1.36, p<0.001) than in controls. Treatment by oral beta blockade appeared to protect from risk (odds ratio 0.77, 95% CI 0.73 to 0.83, p<0.0001), but oral calcium channel antagonists or angiotensin converting enzyme (ACE) inhibitors did not (odds ratios 1.34, 1.24 to 1.44 and 1.16 1.09-1.24, respectively, p<0.0001 in each case). Oral corticosteroid treatment was associated with enhanced risk (odds ratio 1.78, 1.61 to 1.96).

Conclusion: Common pathogenetic mechanisms in ciliary and renal tubular epithelia may explain coincidence of glaucoma and systemic hypertension. The choice of cardiovascular treatment, could substantially influence glaucoma incidence, with beta blockade protecting and ACE inhibitors or calcium channel blockers not affecting underlying risk.

PubMed Disclaimer

References

    1. Stewart PM, Krozowski KS, Gupta A, et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the type II 11β-hydroxysteroid dehydrogenase gene. Lancet 1996;347:88–91. - PubMed
    1. Walker EA, Murray PI, Stewart PM. Immuno-localisation of 11β-hydroxysteroid dehydrogenase isozymes in human ocular tissues. J Endocrinol 1998;156S:P278.
    1. Jick H, Jick S, Derby LE. Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 1991;303:769–72. - PMC - PubMed
    1. Garcia-Rodriguez LA, Perez Gutthan S. Use of the UK General Practitioner Research Database for pharmaco-epidemiology. Br J Clin Pharmacol 1998;45:419–25. - PMC - PubMed
    1. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769–72. - PubMed

Publication types

MeSH terms

Substances